İçeriğe geç
akaturk Akademik ölçüm

Akademisyen

HAKAN EMMUNGİL

PROFESÖR

TRAKYA ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ

  • Ana Dal Sağlık Bilimleri Temel Alanı
  • Yan Dal Romatoloji

Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.

  • Makale 63
  • Proje 0
  • Kitap 0
  • Bildiri 0
  • Patent 0
  • Sanatsal 0
Scopus (SJR) Q1 13 Q2 21 Q3 15 Q4 2
WoS (JCR) Q1 9 Q2 14 Q3 17 Q4 14
TR Index 16 makale

Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.

Üst %1 makale 0
Üst %10 makale 0
Ort. yüzdelik 75.8%
Üst %1 payı 0.0%
Üst %10 payı 0.0%

Makaleler

YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.

Dizin filtreleri

Toplam 63 yayın

Makale listesi

  1. 2025 Real‐World Insights From Türkiye: Biologic DMARDs Usage in Spondyloarthritis Patients With Chronic Kidney Disease International Journal of Rheumatic Diseases DOI 10.1111/1756-185X.70274 YÖKSİS SJR Q3 JCR Q3
  2. 2025 Predicting extra-musculoskeletal and peripheral manifestations and their role on biologic treatment in patients with axial spondyloarthritis: TReasure experience Archives of Rheumatology DOI 10.46497/ArchRheumatol.2025.10670 YÖKSİS TR Index SJR Q3 JCR Q4
  3. 2024 Frequency and the effects of spondyloarthritis-spectrum disorders on the clinical course and management of Takayasu arteritis: an observational retrospective study Clinical Rheumatology DOI 10.1007/s10067-024-06939-y YÖKSİS SJR Q2 JCR Q2
  4. 2024 The importance of speckle tracking echocardiography in the evaluation of cardiac functions in patients with rheumatoid arthritis Archives of Rheumatology DOI 10.46497/ArchRheumatol.2024. YÖKSİS TR Index SJR Q3 JCR Q4
  5. 2024 Comparison of methotrexate and azathioprine as the first-line steroid-sparing immunosuppressive agents in patients with Takayasus arteritis Seminars in Arthritis and Rheumatism DOI 10.1016/j.semarthrit.2024.152446 YÖKSİS SJR Q1 JCR Q1
  6. 2024 Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry Clinical and Experimental Rheumatology DOI 10.55563/clinexprheumatol/2h6ma1 YÖKSİS SJR Q2 JCR Q2
  7. 2023 Clinical and laboratory factors associated with the bamboo spine in patients with axial spondyloarthritis: are there clues for the bamboo spine? Clinical and Experimental Rheumatology DOI 10.55563/clinexprheumatol/eb1zpo YÖKSİS SJR Q2 JCR Q2
  8. 2023 Epidemiological characteristics of hepatitis B and C in patients with inflammatory arthritis: Implications from treasure database Arch Rheumatol DOI 10.46497/ArchRheumatol.2023.9504 YÖKSİS SJR Q1 JCR Q2
  9. 2023 Derivation and validation of adult Still Activity Score (SAS) Elsevier BV DOI 10.1016/j.jbspin.2022.105499 YÖKSİS SJR Q2 JCR Q1
  10. 2023 The predictors of paradoxical reactions, especially psoriasis, to biologic therapy—findings from the TReasure database: a 5-year follow-up study Oxford University Press (OUP) DOI 10.1093/rheumatology/kead318 YÖKSİS SJR Q1 JCR Q1
  11. 2023 Pigmented villus fragments on synovial fluid examination Eur J Rheumatol DOI 10.5152/eurjrheum.2021.20152 YÖKSİS TR Index JCR Q4
  12. 2022 The prevalence of non-vascular pulmonary manifestations in Takayasu’s Arteritis patients: A Retrospective multi-centred Turkish cohort study Scand J Rheumatol DOI 10.1080/03009742.2021.1972535 YÖKSİS SJR Q2 JCR Q4
  13. 2022 EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts Turkish Journal of Medical Sciences DOI 10.55730/1300-0144.5442. YÖKSİS TR Index SJR Q3 JCR Q3
  14. 2022 Imaging in myositis: MRI or 18F-FDG PET/CT? Clinical Rheumatology DOI 10.1007/s10067-022-06141-y YÖKSİS SJR Q2 JCR Q3
  15. 2022 Enteropathic Arthritis Beyond the Criteria INFLAMMATORY BOWEL DISEASES DOI 10.1093/ibd/izab269 YÖKSİS SJR Q1 JCR Q2
  16. 2022 Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all? RHEUMATOLOGY INTERNATIONAL DOI 10.1007/s00296-022-05134-z YÖKSİS SJR Q2 JCR Q2
  17. 2021 Uveitis related factors in patients with spondyloarthritis; TReasure real life results American Journal of Ophthalmology DOI 10.1016/j.ajo.2021.03.026 YÖKSİS SJR Q1 JCR Q1
  18. 2021 GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey Immunotherapy DOI 10.2217/imt-2020-0296 YÖKSİS SJR Q2 JCR Q3
  19. 2021 Biologic treatments in Takayasu's Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumab Seminars in Arthritis and Rheumatism DOI 10.1016/j.semarthrit.2021.09.010 YÖKSİS SJR Q1 JCR Q2
  20. 2021 In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids? Rheumatology International DOI 10.1007/s00296-021-04939-8 YÖKSİS SJR Q2 JCR Q3

Akademisyenlere dön